Chun‐Yi Wu

1.2k total citations
31 papers, 967 citations indexed

About

Chun‐Yi Wu is a scholar working on Molecular Biology, Immunology and Allergy and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Chun‐Yi Wu has authored 31 papers receiving a total of 967 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Molecular Biology, 6 papers in Immunology and Allergy and 5 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Chun‐Yi Wu's work include Cell Adhesion Molecules Research (6 papers), Neuroscience and Neuropharmacology Research (4 papers) and Monoclonal and Polyclonal Antibodies Research (3 papers). Chun‐Yi Wu is often cited by papers focused on Cell Adhesion Molecules Research (6 papers), Neuroscience and Neuropharmacology Research (4 papers) and Monoclonal and Polyclonal Antibodies Research (3 papers). Chun‐Yi Wu collaborates with scholars based in United States, Taiwan and Japan. Chun‐Yi Wu's co-authors include Kit S. Lam, Yoko K. Takada, Yoshikazu Takada, Jun Saegusa, Michael A. Rogawski, Dorota Żółkowska, Satoshi Yamaji, Lee‐Way Jin, Hyun‐Seok Hong and Hank F. Kung and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and Cancer Research.

In The Last Decade

Chun‐Yi Wu

29 papers receiving 958 citations

Peers

Chun‐Yi Wu
Iain Uings United Kingdom
Leila K. Needham United States
Won Hee Jang South Korea
I R Patel United States
Chun‐Yi Wu
Citations per year, relative to Chun‐Yi Wu Chun‐Yi Wu (= 1×) peers Eduardo Domínguez

Countries citing papers authored by Chun‐Yi Wu

Since Specialization
Citations

This map shows the geographic impact of Chun‐Yi Wu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chun‐Yi Wu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chun‐Yi Wu more than expected).

Fields of papers citing papers by Chun‐Yi Wu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Chun‐Yi Wu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chun‐Yi Wu. The network helps show where Chun‐Yi Wu may publish in the future.

Co-authorship network of co-authors of Chun‐Yi Wu

This figure shows the co-authorship network connecting the top 25 collaborators of Chun‐Yi Wu. A scholar is included among the top collaborators of Chun‐Yi Wu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Chun‐Yi Wu. Chun‐Yi Wu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ning, Shu, Enming Xing, Wei Lou, et al.. (2024). LX1 Dual Targets AR Variants and AKR1C3 in Advanced Prostate Cancer Therapy. Cancer Research. 84(21). 3617–3628. 4 indexed citations
2.
Takada, Yoko K., et al.. (2024). The heparin-binding domain of VEGF165 directly binds to integrin αvβ3 and VEGFR2/KDR D1: a potential mechanism of negative regulation of VEGF165 signaling by αvβ3. Frontiers in Cell and Developmental Biology. 12. 1347616–1347616. 4 indexed citations
3.
Wu, Chun‐Yi, Kazutaka Nanba, James M. Luther, et al.. (2024). 7974 Expression of C-X-C Motif Chemokine Receptor 4 (CXCR4) in Aldosterone-Producing Adenomas and Adjacent Non-Functional Adenomas. Journal of the Endocrine Society. 8(Supplement_1).
4.
Bruun, Donald A., Yi‐Je Chen, Chun‐Yi Wu, et al.. (2023). Tolerability and pharmacokinetics of intravenous allopregnanolone with and without midazolam pretreatment in two healthy dogs. Epilepsia Open. 8(2). 666–672. 3 indexed citations
5.
Parikh, Mamta, Chengfei Liu, Chun‐Yi Wu, et al.. (2021). Phase Ib trial of reformulated niclosamide with abiraterone/prednisone in men with castration-resistant prostate cancer. Scientific Reports. 11(1). 6377–6377. 63 indexed citations
6.
Patterson, Edward E., Chun‐Yi Wu, Dorota Żółkowska, et al.. (2021). Intravenous and Intramuscular Allopregnanolone for Early Treatment of Status Epilepticus: Pharmacokinetics, Pharmacodynamics, and Safety in Dogs. Journal of Pharmacology and Experimental Therapeutics. 380(2). 104–113. 5 indexed citations
7.
Żółkowska, Dorota, Chun‐Yi Wu, & Michael A. Rogawski. (2021). Intranasal Allopregnanolone Confers Rapid Seizure Protection: Evidence for Direct Nose-to-Brain Delivery. Neurotherapeutics. 18(1). 544–555. 17 indexed citations
8.
Shi, Zhenrui, Xuesong Wu, Chun‐Yi Wu, et al.. (2021). Bile Acids Improve Psoriasiform Dermatitis through Inhibition of IL-17A Expression and CCL20-CCR6–Mediated Trafficking of T Cells. Journal of Investigative Dermatology. 142(5). 1381–1390.e11. 30 indexed citations
9.
Liu, Chengfei, Cameron M. Armstrong, Shu Ning, et al.. (2021). ARVib suppresses growth of advanced prostate cancer via inhibition of androgen receptor signaling. Oncogene. 40(35). 5379–5392. 18 indexed citations
10.
Zimmermann, Maike, Tao Li, Thomas J. Semrad, et al.. (2020). Oxaliplatin–DNA Adducts as Predictive Biomarkers of FOLFOX Response in Colorectal Cancer: A Potential Treatment Optimization Strategy. Molecular Cancer Therapeutics. 19(4). 1070–1079. 20 indexed citations
11.
Diaz-Ochoa, Vladimir E., G. Walker, Stephanie A. Cevallos, et al.. (2020). Vitamin A supplementation boosts control of antibiotic-resistant Salmonella infection in malnourished mice. PLoS neglected tropical diseases. 14(10). e0008737–e0008737. 2 indexed citations
12.
Chen, Justin, Edward Kim, David R. Gandara, et al.. (2020). Phase I study of the combination of alisertib (MLN8237) and gemcitabine in advanced solid tumors.. Journal of Clinical Oncology. 38(15_suppl). 3589–3589. 1 indexed citations
13.
Mori, Seiji, Naomasa Kawaguchi, Yoshinosuke Hamada, et al.. (2017). The integrin-binding defective FGF2 mutants potently suppress FGF2 signalling and angiogenesis. Bioscience Reports. 37(2). 41 indexed citations
14.
Takada, Yoko K., Feng Yu, Masaaki Fujita, et al.. (2017). Direct binding to integrins and loss of disulfide linkage in interleukin-1β (IL-1β) are involved in the agonistic action of IL-1β. Journal of Biological Chemistry. 292(49). 20067–20075. 15 indexed citations
15.
Yang, Jin, Andrea Schneider, Cecilia Giulivi, et al.. (2017). Open-Label Allopregnanolone Treatment of Men with Fragile X-Associated Tremor/Ataxia Syndrome. Neurotherapeutics. 14(4). 1073–1083. 34 indexed citations
16.
Saegusa, Jun, Satoshi Yamaji, Katsuaki Ieguchi, et al.. (2009). The Direct Binding of Insulin-like Growth Factor-1 (IGF-1) to Integrin αvβ3 Is Involved in IGF-1 Signaling. Journal of Biological Chemistry. 284(36). 24106–24114. 79 indexed citations
17.
Saegusa, Jun, Nobuaki Akakura, Chun‐Yi Wu, et al.. (2008). Pro-inflammatory Secretory Phospholipase A2 Type IIA Binds to Integrins αvβ3 and α4β1 and Induces Proliferation of Monocytic Cells in an Integrin-dependent Manner. Journal of Biological Chemistry. 283(38). 26107–26115. 85 indexed citations
18.
Yao, Nianhuan, Chun‐Yi Wu, Wenwu Xiao, & Kit S. Lam. (2008). Discovery of high‐affinity peptide ligands for vancomycin. Biopolymers. 90(3). 421–432. 13 indexed citations
19.
Mori, Seiji, Chun‐Yi Wu, Satoshi Yamaji, et al.. (2008). Direct Binding of Integrin αvβ3 to FGF1 Plays a Role in FGF1 Signaling. Journal of Biological Chemistry. 283(26). 18066–18075. 117 indexed citations
20.
Maezawa, Izumi, Hyun‐Seok Hong, Ruiwu Liu, et al.. (2007). Congo red and thioflavin‐T analogs detect Aβ oligomers. Journal of Neurochemistry. 104(2). 457–468. 203 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026